Clinical Trial Update: A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MLN7243 (TAK-243) in adults with advanced malignant solid tumors; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumors

Drugs mentioned

• MLN7243 (TAK-243) (MLN7243)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Malignant Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2019-03-14